Skip to main content
Top
Published in: Journal of Clinical Immunology 2/2015

01-02-2015 | Astute Clinician Report

Identification of a Novel Mutation in MAGT1 and Progressive Multifocal Leucoencephalopathy in a 58-Year-Old Man with XMEN Disease

Authors: Fatima Dhalla, Sarah Murray, Ross Sadler, Benjamin Chaigne-Delalande, Tomohiko Sadaoka, Elizabeth Soilleux, Gulbu Uzel, Joanne Miller, Graham Peter Collins, Christian Simon Ross Hatton, Malini Bhole, Berne Ferry, Helen M. Chapel, Jeffrey I. Cohen, Smita Y. Patel

Published in: Journal of Clinical Immunology | Issue 2/2015

Login to get access

Abstract

XMEN disease (X-linked immunodeficiency with Magnesium defect, Epstein-Barr virus infection and Neoplasia) is a novel primary immune deficiency caused by mutations in MAGT1 and characterised by chronic infection with Epstein-Barr virus (EBV), EBV-driven lymphoma, CD4 T-cell lymphopenia, and dysgammaglobulinemia [1]. Functional studies have demonstrated roles for magnesium as a second messenger in T-cell receptor signalling [1], and for NKG2D expression and consequently NK- and CD8 T-cell cytotoxicity [2]. 7 patients have been described in the literature; the oldest died at 45 years and was diagnosed posthumously [13]. We present the case of a 58-year-old Caucasian gentleman with a novel mutation in MAGT1 with the aim of adding to the phenotype of this newly described disease by detailing his clinical course over more than 20 years.
Appendix
Available only for authorised users
Literature
1.
go back to reference Li FY, Chaigne-Delalande B, Kanellopoulou C, Davis JC, Matthews HF, Douek DC, et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature. 2011;475(7357):471–6.CrossRefPubMedCentralPubMed Li FY, Chaigne-Delalande B, Kanellopoulou C, Davis JC, Matthews HF, Douek DC, et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature. 2011;475(7357):471–6.CrossRefPubMedCentralPubMed
2.
go back to reference Chaigne-Delalande B, Li FY, O’Connor GM, Lukacs MJ, Jiang P, Zheng L, et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science. 2013;341(6142):186–91.CrossRefPubMedCentralPubMed Chaigne-Delalande B, Li FY, O’Connor GM, Lukacs MJ, Jiang P, Zheng L, et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science. 2013;341(6142):186–91.CrossRefPubMedCentralPubMed
3.
go back to reference Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood. 2014;123(14):1248–52.CrossRef Li FY, Chaigne-Delalande B, Su H, Uzel G, Matthews H, Lenardo MJ. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood. 2014;123(14):1248–52.CrossRef
4.
go back to reference Sadler R, Bateman EA, Heath V, Patel SY, Schwingshackl PP, Cullinane AC, et al. Establishment of a healthy human range for the whole blood ’OX40′ assay for the detection of antigen-specific CD4+ T cells by flow cytometry. Cytometry B Clin Cytom. 2014. Sadler R, Bateman EA, Heath V, Patel SY, Schwingshackl PP, Cullinane AC, et al. Establishment of a healthy human range for the whole blood ’OX40′ assay for the detection of antigen-specific CD4+ T cells by flow cytometry. Cytometry B Clin Cytom. 2014.
5.
go back to reference Misbah SA, Spickett GP, Zeman A, Esiri MM, Wallington TB, Kurtz JB, et al. Progressive multifocal leucoencephalopathy, sclerosing cholangitis, bronchiectasis and disseminated warts in a patient with primary combined immune deficiency. J Clin Pathol. 1992;45(7):624–7.CrossRefPubMedCentralPubMed Misbah SA, Spickett GP, Zeman A, Esiri MM, Wallington TB, Kurtz JB, et al. Progressive multifocal leucoencephalopathy, sclerosing cholangitis, bronchiectasis and disseminated warts in a patient with primary combined immune deficiency. J Clin Pathol. 1992;45(7):624–7.CrossRefPubMedCentralPubMed
6.
go back to reference Chikezie PU, Greenberg AL. Idiopathic CD4+ T lymphocytopenia presenting as progressive multifocal leukoencephalopathy: case report. Clin Infect Dis. 1997;24(3):526–7.CrossRefPubMed Chikezie PU, Greenberg AL. Idiopathic CD4+ T lymphocytopenia presenting as progressive multifocal leukoencephalopathy: case report. Clin Infect Dis. 1997;24(3):526–7.CrossRefPubMed
7.
go back to reference Haider S, Nafziger D, Gutierrez JA, Brar I, Mateo N, Fogle J. Progressive multifocal leukoencephalopathy and idiopathic CD4 + lymphocytopenia: a case report and review of reported cases. Clin Infect Dis. 2000;31(4):E20–2.CrossRefPubMed Haider S, Nafziger D, Gutierrez JA, Brar I, Mateo N, Fogle J. Progressive multifocal leukoencephalopathy and idiopathic CD4 + lymphocytopenia: a case report and review of reported cases. Clin Infect Dis. 2000;31(4):E20–2.CrossRefPubMed
8.
go back to reference Inhoff O, Doerries K, Doerries R, Scharf J, Groden C, Goerdt S, et al. Disseminated cutaneous Kaposi sarcoma and progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia. Arch Dermatol. 2007;143(5):673–5.PubMed Inhoff O, Doerries K, Doerries R, Scharf J, Groden C, Goerdt S, et al. Disseminated cutaneous Kaposi sarcoma and progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia. Arch Dermatol. 2007;143(5):673–5.PubMed
9.
go back to reference Delgado-Alvarado M, Sedano MJ, González-Quintanilla V, de Lucas EM, Polo JM, Berciano J. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci. 2013;327(1–2):75–9.CrossRefPubMed Delgado-Alvarado M, Sedano MJ, González-Quintanilla V, de Lucas EM, Polo JM, Berciano J. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci. 2013;327(1–2):75–9.CrossRefPubMed
10.
go back to reference Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol. 2009;10(8):816–24.CrossRefPubMed Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol. 2009;10(8):816–24.CrossRefPubMed
11.
go back to reference Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25(3):471–506.CrossRefPubMedCentralPubMed Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25(3):471–506.CrossRefPubMedCentralPubMed
12.
go back to reference Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med. 1988;318(5):301–5.CrossRefPubMed Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med. 1988;318(5):301–5.CrossRefPubMed
13.
go back to reference Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol. 1996;70(10):7004–12.PubMedCentralPubMed Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol. 1996;70(10):7004–12.PubMedCentralPubMed
14.
Metadata
Title
Identification of a Novel Mutation in MAGT1 and Progressive Multifocal Leucoencephalopathy in a 58-Year-Old Man with XMEN Disease
Authors
Fatima Dhalla
Sarah Murray
Ross Sadler
Benjamin Chaigne-Delalande
Tomohiko Sadaoka
Elizabeth Soilleux
Gulbu Uzel
Joanne Miller
Graham Peter Collins
Christian Simon Ross Hatton
Malini Bhole
Berne Ferry
Helen M. Chapel
Jeffrey I. Cohen
Smita Y. Patel
Publication date
01-02-2015
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 2/2015
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-014-0116-2

Other articles of this Issue 2/2015

Journal of Clinical Immunology 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine